We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · December 18, 2020

Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy

Movement Disorders: Official Journal of the Movement Disorder Society

 

Additional Info

Movement Disorders: Official Journal of the Movement Disorder Society
A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy
Mov. Disord. 2020 Nov 01;35(11)957-1965, WG Meissner, AP Traon, A Foubert-Samier, G Galabova, M Galitzky, A Kutzelnigg, B Laurens, P Lührs, R Medori, P Péran, U Sabatini, S Vergnet, D Volc, W Poewe, A Schneeberger, G Staffler, O Rascol, On Behalf Of The Aff Investigators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading